|
Market Closed -
Swiss Exchange
11:31:41 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 43.95 CHF | -0.45% |
|
-0.23% | - |
| 10-16 | Samsung Biologics' PolyPeptide Offer Tops 87% Participation Rate | MT |
| 10-13 | South Korea's Samsung Biologics Secures 88% Stake in PolyPeptide Group Amid Takeover Bid | MT |
Company Valuation: PolyPeptide Group AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,372 | 843.9 | 620.1 | 995.4 | 925.9 | 1,566 | - | - |
| Change | - | -80.7% | -26.52% | 60.52% | -6.98% | 69.09% | - | - |
| Enterprise Value (EV) 1 | 4,265 | 838.1 | 638.1 | 1,021 | 981.9 | 1,667 | 1,696 | 1,704 |
| Change | - | -80.35% | -23.87% | 60.05% | -3.85% | 69.73% | 1.8% | 0.44% |
| P/E | 90x | 107x | -12.1x | -51.1x | -43.9x | 58.4x | 31x | 20.1x |
| PBR | 10.1x | 2x | 1.64x | 2.8x | 2.73x | 3.79x | 3.39x | 2.89x |
| PEG | - | -1.3x | 0x | 0.8x | -5.18x | -0x | 0.4x | 0.4x |
| Capitalization / Revenue | 15.5x | 3x | 1.91x | 2.94x | 2.36x | 3.12x | 2.72x | 2.35x |
| EV / Revenue | 15.1x | 2.98x | 1.96x | 3.01x | 2.51x | 3.32x | 2.95x | 2.56x |
| EV / EBITDA | 50.3x | 21.7x | -106x | 40.3x | 21x | 17.2x | 13.9x | 10.5x |
| EV / EBIT | 66.4x | 66.5x | -17.5x | -139x | 113x | 34.1x | 23.8x | 15.4x |
| EV / FCF | -257x | -11.4x | -31.5x | 420x | -31.3x | -36.2x | -55.6x | -131x |
| FCF Yield | -0.39% | -8.75% | -3.17% | 0.24% | -3.2% | -2.76% | -1.8% | -0.76% |
| Dividend per Share 2 | 0.2909 | - | - | - | - | - | 0.065 | 0.255 |
| Rate of return | 0.22% | - | - | - | - | - | 0.14% | 0.54% |
| EPS 2 | 1.47 | 0.24 | -1.56 | -0.59 | -0.64 | 0.8123 | 1.531 | 2.364 |
| Distribution rate | 19.8% | - | - | - | - | - | 4.25% | 10.8% |
| Net sales 1 | 282.1 | 281 | 324.9 | 338.8 | 391.9 | 501.9 | 576 | 666.5 |
| EBITDA 1 | 84.8 | 38.67 | -6 | 25.35 | 46.76 | 96.71 | 122.2 | 161.7 |
| EBIT 1 | 64.2 | 12.61 | -36.47 | -7.364 | 8.689 | 48.81 | 71.22 | 110.4 |
| Net income 1 | 47.26 | 7.767 | -51.44 | -19.56 | -21.17 | 23.5 | 45.23 | 78.24 |
| Net Debt 1 | -106.9 | -5.804 | 17.96 | 25.84 | 55.98 | 101 | 130.9 | 138.3 |
| Reference price 2 | 132.36 | 25.62 | 18.82 | 30.18 | 28.06 | 47.42 | 47.42 | 47.42 |
| Nbr of stocks (in thousands) | 33,031 | 32,938 | 32,944 | 32,984 | 32,991 | 33,016 | - | - |
| Announcement Date | 3/15/22 | 3/14/23 | 3/12/24 | 3/11/25 | 3/12/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 437.88B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PPGN Stock
- PPGNE Stock
- Valuation PolyPeptide Group AG
Select your edition
All financial news and data tailored to specific country editions
